This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papandreou, C. N. Articles by Logothetis, C. J. Search for Related Content PubMed PubMed Citation Articles by Papandreou, C. N. Articles by Logothetis, C. J. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Small Molecules

Bortezomib as a Potential Treatment for Prostate Cancer

Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Androgen ablation and chemotherapy provide effective palliation for most patients with advanced prostate cancer, but eventually progressing androgen-independent prostate cancer threatens the lives of patients usually within a few years, mandating improvement in therapy. Proteasome inhibition has been proposed as a therapy target for the treatment of solid and hematological malignancies. The proteasome is a ubiquitous enzyme complex that is a hub for the regulation of many intracellular regulatory pathways; because of its essential function, this enzyme has become a new target for cancer treatment. Studies with bortezomib (VELCADE, formerly known as PS-341) and other proteasome inhibitors indicate that cancer cells are especially dependent on the proteasome for survival, and several mechanisms used by prostate cancer cells require proteasome function. Bortezomib has been studied extensively in vitro and in vivo, and anticancer activity has been seen in cell and animal models for several solid tumor types, including prostate cancer. A Phase I trial to determine the maximum tolerated dose of once-weekly bortezomib has been completed. This trial included a large fraction of patients with androgen-independent prostate cancer. The maximum tolerated dose was reached at 1.6 mg/m². A correlation was seen among bortezomib dose, proteasome inhibition, and positive modulation of serum prostate-specific antigen. There was also evidence of down-regulation of serum interleukin 6, a downstream nuclear factor B effector. This Phase I trial and preclinical studies support additional testing of bortezomib in combination with radiation or chemotherapy for androgen-independent prostate cancer.

This article has been cited by other articles:

				S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino, and B. Bonavida Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells J. Immunol., May 1, 2008; 180(9): 6199 - 6210. [Abstract] [Full Text] [PDF]

				R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215. [Abstract] [Full Text] [PDF]

				D. Chen, Q. C. Cui, H. Yang, and Q. P. Dou Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity Cancer Res., November 1, 2006; 66(21): 10425 - 10433. [Abstract] [Full Text] [PDF]

				S. Ruiz, Y. Krupnik, M. Keating, J. Chandra, M. Palladino, and D. McConkey The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther., July 1, 2006; 5(7): 1836 - 1843. [Abstract] [Full Text] [PDF]

				S. Nam, D. Kim, J. Q. Cheng, S. Zhang, J.-H. Lee, R. Buettner, J. Mirosevich, F. Y. Lee, and R. Jove Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells Cancer Res., October 15, 2005; 65(20): 9185 - 9189. [Abstract] [Full Text] [PDF]

				Y.-T. Huang, S.-L. Pan, J.-H. Guh, Y.-L. Chang, F.-Y. Lee, S.-C. Kuo, and C.-M. Teng YC-1 suppresses constitutive nuclear factor-{kappa}B activation and induces apoptosis in human prostate cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1628 - 1635. [Abstract] [Full Text] [PDF]

				P. Andre, S. Cisternino, F. Chiadmi, A. Toledano, J. Schlatter, O. Fain, and J.-E. Fontan Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial Ann. Pharmacother., September 1, 2005; 39(9): 1462 - 1466. [Abstract] [Full Text] [PDF]

				J.-Z. Qin, J. Ziffra, L. Stennett, B. Bodner, B. K. Bonish, V. Chaturvedi, F. Bennett, P. M. Pollock, J. M. Trent, M. J.C. Hendrix, et al. Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells Cancer Res., July 15, 2005; 65(14): 6282 - 6293. [Abstract] [Full Text] [PDF]

				M. H. Shah, D. Young, H. L. Kindler, I. Webb, B. Kleiber, J. Wright, and M. Grever Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6111 - 6118. [Abstract] [Full Text] [PDF]